BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shen G, Zhao F, Huo X, Ren D, Du F, Zheng F, Zhao J. Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment. Front Oncol 2021;11:632357. [PMID: 34367947 DOI: 10.3389/fonc.2021.632357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Bueno Muiño C, Martín M, Del Monte-Millán M, García-Saénz JÁ, López-Tarruella S. HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping. Cancers (Basel) 2022;14:512. [PMID: 35158778 DOI: 10.3390/cancers14030512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 An J, Peng C, Tang H, Liu X, Peng F. New Advances in the Research of Resistance to Neoadjuvant Chemotherapy in Breast Cancer. Int J Mol Sci 2021;22:9644. [PMID: 34502549 DOI: 10.3390/ijms22179644] [Reference Citation Analysis]
3 Ferrando-díez A, Felip E, Pous A, Bergamino Sirven M, Margelí M. Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. Cancers 2022;14:3305. [DOI: 10.3390/cancers14143305] [Reference Citation Analysis]
4 Derouane F, van Marcke C, Berlière M, Gerday A, Fellah L, Leconte I, Van Bockstal MR, Galant C, Corbet C, Duhoux FP. Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine. Cancers 2022;14:3876. [DOI: 10.3390/cancers14163876] [Reference Citation Analysis]